Eris Lifesciences Posts ₹1.2 Billion Profit In Q2 On ₹7.92 Billion Revenue

Eris Lifesciences Ltd., a leading player in India’s chronic and lifestyle-focused pharmaceutical market, announced its Q2 FY26 financial results with consolidated revenue from operations at ₹7.92 billion and net profit of ₹1.2 billion. The company’s performance reflects a 31.2 percent year-on-year surge in profit and a 6.3 percent rise in revenue, supported by strategic portfolio management and cost discipline.

The results underscore Eris’ commitment to high-margin therapies and its focus on sustainable growth.

Key Highlights From The Quarterly Update:  

• Revenue rose 6.3 percent YoY to ₹7.92 billion, led by growth in cardiometabolic and neuropsychiatry segments  
• Net profit surged 31.2 percent YoY to ₹1.2 billion, driven by improved operational efficiency  
• EBITDA increased 7 percent YoY to ₹2.88 billion, with margins expanding to 36.3 percent from 33 percent  
• The company continues to optimize its product mix toward chronic therapies with higher profitability  
• Management reaffirmed its focus on digital engagement, physician outreach, and compliance-driven growth  
• Eris is exploring new launches in dermatology and endocrinology to diversify its portfolio  
• Strategic acquisitions and partnerships remain key to expanding therapeutic coverage and market reach

Eris Lifesciences’ Q2 performance reflects its operational strength and strategic clarity in India’s specialty pharma landscape.

Sources: Business Upturn